Ra Eeles

List of Publications by Year
in descending order

184 papers	26,396 citations	11608 70 h-index	6979 154 g-index
202 all docs	202 docs citations	202 times ranked	29700 citing authors

#	Article	IF	Citations
1	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	3.8	1,898
2	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 2015, 373, 1697-1708.	13.9	1,796
3	REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. American Journal of Human Genetics, 2016, 99, 877-885.	2.6	1,555
4	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453.	13.9	1,205
5	The evolutionary history of lethal metastatic prostate cancer. Nature, 2015, 520, 353-357.	13.7	1,185
6	Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genetics, 2002, 31, 55-59.	9.4	1,001
7	Multiple newly identified loci associated with prostate cancer susceptibility. Nature Genetics, 2008, 40, 316-321.	9.4	796
8	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	9.4	652
9	Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. Journal of Clinical Oncology, 2013, 31, 1748-1757.	0.8	641
10	Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Human Molecular Genetics, 1998, 7, 507-515.	1.4	578
11	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	9.4	492
12	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics, 2014, 46, 1103-1109.	9.4	408
13	Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nature Genetics, 2015, 47, 736-745.	9.4	395
14	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
15	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nature Genetics, 2009, 41, 1116-1121.	9.4	389
16	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics, 2015, 47, 367-372.	9.4	380
17	Prevention and early detection of prostate cancer. Lancet Oncology, The, 2014, 15, e484-e492.	5.1	372
18	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356

#	Article	IF	Citations
19	Two Percent of Men with Early-Onset Prostate Cancer Harbor Germline Mutations in the BRCA2 Gene. American Journal of Human Genetics, 2003, 72, 1-12.	2.6	332
20	BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. British Journal of Cancer, 2011, 105, 1230-1234.	2.9	320
21	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncology, The, 2014, 15, 1521-1532.	5.1	291
22	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
23	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. European Urology, 2015, 68, 186-193.	0.9	279
24	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 126-135.	1.1	278
25	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	0.9	278
26	Multiple loci on 8q24 associated with prostate cancer susceptibility. Nature Genetics, 2009, 41, 1058-1060.	9.4	273
27	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	9.4	264
28	Germline BRCA1 mutations increase prostate cancer risk. British Journal of Cancer, 2012, 106, 1697-1701.	2.9	251
29	A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nature Genetics, 1992, 2, 132-134.	9.4	241
30	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
31	Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nature Reviews Clinical Oncology, 2014, 11, 260-271.	12.5	218
32	The genetic epidemiology of prostate cancer and its clinical implications. Nature Reviews Urology, 2014, 11, 18-31.	1.9	207
33	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499.	0.9	195
34	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics, 2018, 50, 682-692.	9.4	182
35	Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African Descent. Prostate Cancer, 2013, 2013, 1-12.	0.4	180
36	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174

#	Article	IF	Citations
37	Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort. British Journal of Cancer, 2002, 86, 1209-1216.	2.9	173
38	Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nature Communications, 2019, 10, 2154.	5.8	172
39	Comprehensive Functional Annotation of 77 Prostate Cancer Risk Loci. PLoS Genetics, 2014, 10, e1004102.	1.5	167
40	Head and neck sarcomas: prognostic factors and implications for treatment. British Journal of Cancer, 1993, 68, 201-207.	2.9	165
41	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
42	Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. British Journal of Cancer, 2011, 104, 1656-1663.	2.9	153
43	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ: British Medical Journal, 2018, 360, j5757.	2.4	153
44	Juggling roles and expectations: dilemmas faced by women talking to relatives about cancer and genetic testing. Psychology and Health, 2004, 19, 439-455.	1.2	152
45	Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. Nature Genetics, 2013, 45, 686-689.	9.4	149
46	Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL Consortium. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2052-2061.	1.1	148
47	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. JAMA Oncology, 2017, 3, 1634.	3.4	148
48	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842.	0.9	148
49	Androgen receptor polymorphisms: Association with prostate cancer risk, relapse and overall survival. , 1999, 84, 458-465.		127
50	Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. British Journal of Cancer, 2014, 110, 1663-1672.	2.9	126
51	The role of BRCA1 and BRCA2 in prostate cancer. Asian Journal of Andrology, 2012, 14, 409-414.	0.8	124
52	Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. European Urology, 2020, 77, 24-35.	0.9	124
53	Large-scale transcriptome-wide association study identifies new prostate cancer risk regions. Nature Communications, 2018, 9, 4079.	5.8	121
54	Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. Nature Genetics, 2017, 49, 1133-1140.	9.4	120

#	Article	IF	Citations
55	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics, 2013, 22, 408-415.	1.4	118
56	A Review of Prostate Cancer Genome-Wide Association Studies (GWAS). Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 845-857.	1.1	118
57	Communication about genetic testing in families of male BRCA1/2 carriers and non-carriers: patterns, priorities and problems. Clinical Genetics, 2005, 67, 492-502.	1.0	105
58	Germ-Line Mutations in Mismatch Repair Genes Associated with Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2460-2467.	1.1	103
59	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Human Molecular Genetics, 2013, 22, 2520-2528.	1.4	100
60	Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. Cancer Research, 2016, 76, 5103-5114.	0.4	100
61	Detection of point mutations in the p53 gene: Comparison of single-strand conformation polymorphism, constant denaturant gel electrophoresis, and hydroxylamine and osmium tetroxide techniques. Human Mutation, 1993, 2, 58-66.	1.1	99
62	Radiogenomics: Radiobiology Enters the Era of Big Data and Team Science. International Journal of Radiation Oncology Biology Physics, 2014, 89, 709-713.	0.4	99
63	Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial. Journal of Clinical Oncology, 2015, 33, 4138-4144.	0.8	98
64	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
65	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	5.8	88
66	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
67	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. Genetics in Medicine, 2015, 17, 789-795.	1.1	87
68	Guilt, blame and responsibility: men's understanding of their role in the transmission of BRCA1/2 mutations within their family. Sociology of Health and Illness, 2006, 28, 060926022052001-???.	1.1	86
69	Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nature Communications, 2018, 9, 3707.	5.8	86
70	Allelic imbalance, including deletion ofPTEN/MMAC1, at the Cowden disease locus on 10q22-23, in hamartomas from patients with cowden syndrome and germlinePTEN mutation. , 1998, 21, 61-69.		85
71	Prevalence of theHOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. Annals of Oncology, 2015, 26, 756-761.	0.6	85
72	Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU International, 2011, 107, 28-39.	1.3	83

#	Article	IF	Citations
73	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. Nature Communications, 2020, 11, 3353.	5.8	75
74	The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine. PLoS ONE, 2010, 5, e13363.	1.1	73
75	Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. European Journal of Cancer Care, 2005, 14, 272-281.	0.7	72
76	Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. Journal of the National Cancer Institute, 2020, 112, 179-190.	3.0	71
77	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. Genome Research, 2015, 25, 814-824.	2.4	69
78	Menâ€™s Decision-Making About Predictive BRCA1/2 Testing: The Role of Family. Journal of Genetic Counseling, 2005, 14, 207-217.	0.9	67
79	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Human Molecular Genetics, 2015, 24, 5589-5602.	1.4	67
80	A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 193-200.	1.1	66
81	Generalizability of established prostate cancer risk variants in men of <scp>A</scp>frican ancestry. International Journal of Cancer, 2015, 136, 1210-1217.	2.3	62
82	Non-Hodgkin's lymphoma presenting with extradural spinal cord compression: functional outcome and survival. British Journal of Cancer, 1991, 63, 126-129.	2.9	60
83	Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. Nature Communications, 2018, 9, 1340.	5.8	58
84	Genetic predisposition to prostate cancer. Prostate Cancer and Prostatic Diseases, 1999, 2, 9-15.	2.0	57
85	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. Journal of the National Cancer Institute, 2017, 109, .	3.0	57
86	Unravelling the genetics of prostate cancer. American Journal of Medical Genetics Part A, 2004, 129C, 65-73.	2.4	56
87	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1121-1129.	1.1	56
88	Polygenic risk-tailored screening for prostate cancer: A benefitâ€“harm and cost-effectiveness modelling study. PLoS Medicine, 2019, 16, e1002998.	3.9	56
89	Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. Familial Cancer, 2017, 16, 433-440.	0.9	52
90	Evaluating Genetic Risk for Prostate Cancer among Japanese and Latinos. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2048-2058.	1.1	51

#	Article	IF	Citations
91	Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. International Journal of Epidemiology, 2019, 48, 1416-1424.	0.9	51
92	Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. Human Molecular Genetics, 2015, 24, 5603-5618.	1.4	50
93	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nature Communications, 2016, 7, 10979.	5.8	50
94	Quantifying the Genetic Correlation between Multiple Cancer Types. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1427-1435.	1.1	48
95	Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. European Urology, 2019, 76, 329-337.	0.9	48
96	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncology, The, 2021, 22, 1618-1631.	5.1	48
97	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 2018, 9, 4616.	5.8	43
98	Identification of Novel Susceptibility Loci and Genes for Prostate Cancer Risk: A Transcriptome-Wide Association Study in Over 140,000 European Descendants. Cancer Research, 2019, 79, 3192-3204.	0.4	43
99	Rare Germ Line CHEK2 Variants Identified in Breast Cancer Families Encode Proteins That Show Impaired Activation. Cancer Research, 2006, 66, 8966-8970.	0.4	40
100	Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. Nature Communications, 2017, 8, 1892.	5.8	40
101	Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease. British Journal of Cancer, 2018, 119, 96-104.	2.9	40
102	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nature Communications, 2021, 12, 1236.	5.8	40
103	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
104	Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk. European Urology, 2021, 80, 134-138.	0.9	39
105	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. European Urology Oncology, 2021, 4, 570-579.	2.6	38
106	Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. Human Genetics, 2016, 135, 923-938.	1.8	37
107	Identification of four new susceptibility loci for testicular germ cell tumour. Nature Communications, 2015, 6, 8690.	5.8	36
108	Immunohistochemical expression of BRCA2 protein and allelic loss at theBRCA2 locus in prostate cancer. , 1998, 78, 1-7.		34

#	Article	IF	Citations
109	Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (<scp>SNP</scp>) profiles in an active surveillance cohort. BJU International, 2013, 112, 666-673.	1.3	34
110	Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer. PLoS Genetics, 2014, 10, e1004129.	1.5	34
111	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. PLoS Genetics, 2017, 13, e1007001.	1.5	34
112	Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. British Journal of Cancer, 2015, 113, 1086-1093.	2.9	32
113	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. European Urology, 2020, 78, 316-320.	0.9	32
114	Reply to â€œVariation in KLK genes, prostate-specific antigen and risk of prostate cancerâ€• Nature Genetics, 2008, 40, 1035-1036.	9.4	31
115	Multi-stage genome-wide association study identifies new susceptibility locus for testicular germ cell tumour on chromosome 3q25. Human Molecular Genetics, 2015, 24, 1169-1176.	1.4	31
116	DESNT: A Poor Prognosis Category of Human Prostate Cancer. European Urology Focus, 2018, 4, 842-850.	1.6	30
117	Homeobox B13 G84E Mutation and Prostate Cancer Risk. European Urology, 2019, 75, 834-845.	0.9	28
118	An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. Nature Communications, 2020, 11, 3905.	5.8	28
119	Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. European Urology, 2021, 79, 353-361.	0.9	28
120	The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. Oncologist, 2016, 21, 716-722.	1.9	27
121	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1731-1738.	1.1	27
122	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
123	Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. Radiology, 2021, 299, 494-507.	3.6	26
124	Functional Analysis Identifies DamagingCHEK2Missense Variants Associated with Increased Cancer Risk. Cancer Research, 2022, 82, 615-631.	0.4	26
125	FRMD6 has tumor suppressor functions in prostate cancer. Oncogene, 2021, 40, 763-776.	2.6	24
126	Africanâ€specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. International Journal of Cancer, 2021, 148, 99-105.	2.3	24

#	Article	IF	Citations
127	The psychological impact of undergoing genetic-risk profiling in men with a family history of prostate cancer. Psycho-Oncology, 2015, 24, 1492-1499.	1.0	23
128	Marital status and prostate cancer incidence: a pooled analysis of 12 caseâ€“control studies from the PRACTICAL consortium. European Journal of Epidemiology, 2021, 36, 913-925.	2.5	23
129	Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease. Cancers, 2021, 13, 760.	1.7	22
130	Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology. European Urology, 2018, 74, 248-252.	0.9	20
131	Men with a susceptibility to prostate cancer and the role of genetic based screening. Translational Andrology and Urology, 2018, 7, 61-69.	0.6	19
132	Patterns of recurrence after prostate bed radiotherapy. Radiotherapy and Oncology, 2019, 141, 174-180.	0.3	19
133	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. Journal of Pathology: Clinical Research, 2021, 7, 311-325.	1.3	19
134	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	3.0	19
135	Genetic predisposition to prostate cancer: an update. Familial Cancer, 2022, 21, 101-114.	0.9	18
136	A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population. Oncotarget, 2016, 7, 21393-21403.	0.8	18
137	Delivering cancer genetics services-new ways of working. Familial Cancer, 2007, 6, 163-167.	0.9	17
138	Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions. Human Molecular Genetics, 2015, 24, 7406-7420.	1.4	17
139	Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma. Blood, 2018, 132, 2040-2052.	0.6	17
140	An improved high throughput heteroduplex mutation detection system for screeningBRCA2 mutations?fluorescent mutation detection (F-MD). Human Mutation, 2001, 17, 220-232.	1.1	16
141	Analysis of Over 140,000 European Descendants Identifies Genetically Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk. Cancer Research, 2019, 79, 4592-4598.	0.4	16
142	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers, 2020, 12, 3254.	1.7	16
143	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 532-541.	2.0	16
144	Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. International Journal of Epidemiology, 2023, 52, 71-86.	0.9	16

#	Article	IF	Citations
145	â€œItâ€™s all very well reading the letters in the genome, but itâ€™s a long way to being able to writeâ€: Menâ€™s interpretations of undergoing genetic profiling to determine future risk of prostate cancer. Familial Cancer, 2014, 13, 625-635.	0.9	15
146	The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening. BJU International, 2022, 129, 325-336.	1.3	15
147	Multicentric breast cancer: clonality and prognostic studies. Breast Cancer Research and Treatment, 2011, 129, 703-716.	1.1	14
148	The effect of sample size on polygenic hazard models for prostate cancer. European Journal of Human Genetics, 2020, 28, 1467-1475.	1.4	14
149	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer and Prostatic Diseases, 2022, 25, 755-761.	2.0	14
150	Germline genetic profiling in prostate cancer: latest developments and potential clinical applications. Future Science OA, 2016, 2, FSO87.	0.9	13
151	LocusExplorer: a user-friendly tool for integrated visualization of human genetic association data and biological annotations. Bioinformatics, 2016, 32, 949-951.	1.8	13
152	Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer. Psycho-Oncology, 2017, 26, 1987-1993.	1.0	12
153	Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups. British Journal of Cancer, 2022, 126, 1366-1373.	2.9	12
154	Delivery of cancer genetics services: The Royal Marsden telephone clinic model. Familial Cancer, 2007, 6, 213-219.	0.9	11
155	Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond. Future Oncology, 2014, 10, 1679-1694.	1.1	11
156	Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT. Prostate Cancer and Prostatic Diseases, 2020, 23, 333-342.	2.0	10
157	Common genetic variants associated with disease from genomeâ€wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis. BJU International, 2013, 111, 1148-1155.	1.3	9
158	Psychosocial impact of undergoing prostate cancer screening for men with <scp>BRCA</scp>1 or <scp>BRCA</scp>2 mutations. BJU International, 2019, 123, 284-292.	1.3	9
159	Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. Prostate Cancer and Prostatic Diseases, 2022, 25, 229-237.	2.0	9
160	Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer. Prostate Cancer and Prostatic Diseases, 2003, 6, 12-14.	2.0	8
161	The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 202.e19-202.e28.	0.8	8
162	Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer and Prostatic Diseases, 2018, 21, 228-237.	2.0	8

#	Article	IF	Citations
163	Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer. Oncotarget, 2018, 9, 12630-12638.	0.8	8
164	Genetic testing for BRCA1: effects of a randomised study of knowledge provision on interest in testing and long term test uptake; implications for the NICE guidelines. Familial Cancer, 2009, 8, 5-13.	0.9	7
165	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. British Journal of Cancer, 2017, 117, 734-743.	2.9	7
166	Diffusion-weighted MRI for detecting prostate tumour in men at increased genetic risk. European Journal of Radiology Open, 2014, 1, 22-27.	0.7	6
167	Diagnosis and Management of Hereditary Carcinoids. Recent Results in Cancer Research, 2016, 205, 149-168.	1.8	6
168	Prostate Cancer Risk by BRCA2 Genomic Regions. European Urology, 2020, 78, 494-497.	0.9	6
169	Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals. Human Genetics and Genomics Advances, 2021, 2, 100041.	1.0	6
170	Prostate cancer genome-wide association study from 89,000 men using the OncoArray chip to identify novel prostate cancer susceptibility loci.. Journal of Clinical Oncology, 2016, 34, 1525-1525.	0.8	6
171	The Clinical Genetics of Prostate Cancer. Hereditary Cancer in Clinical Practice, 2004, 2, 111.	0.6	5
172	Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Caseâ€Control Sequencing Studies. Genetic Epidemiology, 2016, 40, 461-469.	0.6	5
173	Runs of homozygosity and testicular cancer risk. Andrology, 2019, 7, 555-564.	1.9	5
174	KLK3 SNPâ€“SNP interactions for prediction of prostate cancer aggressiveness. Scientific Reports, 2021, 11, 9264.	1.6	5
175	Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk. Current Genetic Medicine Reports, 2021, 9, 47-58.	1.9	5
176	seXY: a tool for sex inference from genotype arrays. Bioinformatics, 2017, 33, 561-563.	1.8	4
177	Baseline and post prophylactic tubalâ€“ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers. Familial Cancer, 2014, 13, 197-203.	0.9	3
178	RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 58-66.	1.1	3
179	The New Genomics Era: Integration of genomics into mainstream oncology and implications for psychoâ€oncological care. Psycho-Oncology, 2020, 29, 453-460.	1.0	3
180	Genetics of prostate cancer and its utility in treatment and screening. Advances in Genetics, 2021, 108, 147-199.	0.8	3

#	Article	IF	Citations
181	The genetics of breast cancer. The Journal of the British Menopause Society, 2002, 8, 24-29.	1.3	1
182	Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. , 1998, 78, 1.		1
183	P386: Screening for endometrial cancer in a high-risk population (Hereditary Non Polyposis) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	0.9	0
184	Abstract LB011: Meta-analysis in more than 80,000 men of African ancestry identified nine novel variants associated with prostate cancer. , 2021, , .		0